Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722061 | 1.00 | CYP1A2 (0.36) | CYP1A2PREPSIGMAR1TSHRSHBG | |
| SCHEMBL24919801 | 0.92 | LMNA (0.34) | TSHR | |
| Ammonia Solution, Strong SCHEMBL10451786 | 0.77 | CYP1A2 (0.37) | CYP1A2SIGMAR1TSHRSHBGEPHX1 | |
| SCHEMBL14914768 | 0.77 | CYP1A2 (0.33) | CYP1A2SIGMAR1TSHRSHBGEPHX1 | |
| SCHEMBL8794955 | 0.77 | PREP (0.40) | PREP | |
| SCHEMBL14874307 | 0.76 | CYP1A2 (0.36) | CYP1A2SIGMAR1TSHRSHBGEPHX1 | |
| Ammonia Solution, Strong SCHEMBL8705741 | 0.76 | CYP1A2 (0.36) | CYP1A2SIGMAR1TSHRSHBGEPHX1 | |
| SCHEMBL14914859 | 0.76 | CYP1A2 (0.36) | CYP1A2SIGMAR1TSHRSHBGEPHX1 | |
| SCHEMBL19706465 | 0.76 | SHBG (0.46) | CYP1A2PREPSHBGEPHX1 | |
| Bromide SCHEMBL9388963 | 0.75 | CYP1A2 (0.35) | CYP1A2SIGMAR1TSHRSHBGEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039208-A1 | Process for making n-aryl-anthranilic acids and their derivatives | CHEN MICHAEL HUAI GU (US) | 2004-02-26 | — | — | US | disclosed |
| EP-1313694-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002018319-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039208-A1 | Process for making n-aryl-anthranilic acids and their derivatives | AADAC, AHR, AADAT | CYP1A2 37/4885PREP 255/4885SIGMAR1 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.